# Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct06259058/  
OnCo record `nct06259058` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer is a phase 1/2, randomised interventional study registered as NCT06259058 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 96 participants, started 2024-04-01 and due to reach its primary completion in 2026-04-01. Interventions recorded: Irinotecan liposome injection; Oxaliplatin; 5-Fluorouracil; Leucovorin; SBRT. Conditions listed: Pancreatic Cancer. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: "* Histologically or cytologically proven pancreatic ductal adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06259058
- Phase: 1/2
- Setting: Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer: a Phase Ib/II, Multicenter, Open-label Trial
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 96

## Sources

- ClinicalTrials.gov NCT06259058: https://clinicaltrials.gov/study/NCT06259058

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06259058.json